Kazia Therapeutics Ltd. KZIA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Kazia Therapeutics Ltd. (KZIA) is a healthcare company listed in the US with a market value of about $103M. In fiscal year 2025 it had revenue of $27426 and net income of -$14M, a net margin of -49290.5%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Kazia Therapeutics
Kazia Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $301926 in 2016 to $27426 in 2025, a decline of about 23.4% a year. It was profitable in 0 of the last 10 years in our data.
Score: 0.4 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27426 | $2M | $0 | $0 | $11M | — | — | $87875 | $191347 | $301926 |
| Net income | -$14M | -$18M | -$14M | -$17M | -$6M | -$9M | -$7M | -$4M | -$8M | -$9M |
| Free cash flow | — | — | — | — | — | — | — | — | -$9M | -$9M |
| EPS (diluted) | $-0.87 | $-1.15 | $-0.87 | $-1.11 | $-0.41 | $-0.55 | $-0.46 | $-0.29 | $-0.53 | $-0.58 |
| Net margin | -49290.5% | -1160.2% | — | — | -55.5% | — | — | -5074.8% | -4285.1% | -2971.2% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Kazia Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Kazia Therapeutics pay a dividend?
Not currently.
Is Kazia Therapeutics a good stock to buy?
We do not give buy or sell advice. Kazia Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.